Obesity drugs show liver benefits, but access remains limited to specific patients

A medication that has become synonymous with weight loss is now showing unexpected benefits for the liver—but only for a carefully selected group of patients, and only under strict conditions.

Ozempic, which contains semaglutida, was originally approved to treat type 2 diabetes. In recent years, its use has expanded dramatically into obesity treatment, and now researchers are studying what it can do for a silent liver disease that affects roughly one in three adults worldwide. That disease, metabolic dysfunction-associated fatty liver disease (MASLD), often progresses to a more dangerous form called metabolic steatohepatitis (MASH), which can lead to cirrhosis, liver cancer, and the need for transplantation. For decades, the only real options were lifestyle changes or, in some cases, weight-loss surgery. There were no reliable drugs. The arrival of GLP-1 agonists like semaglutida, and dual GIP/GLP-1 drugs like tirzepatida, has changed that calculus.

The evidence is striking. In the ESSENCE trial, conducted by Novo Nordisk across multiple countries including the United States, Europe, Asia, and Latin America, nearly 63 percent of patients treated with semaglutida achieved resolution of their liver disease without worsening fibrosis, compared to just 34 percent on placebo. More than a third showed actual improvement in their fibrosis stage. Weight loss exceeded 10 percent over 72 weeks. The SYNERGY-NASH trial, run by Eli Lilly, tested tirzepatida and found resolution rates between 44 and 62 percent depending on dose—again, far above placebo. Both drugs reduced liver fat and total body weight substantially. Real-world data suggests they also lower the risk of liver and heart events, hospitalizations, and death in people with diabetes and fatty liver disease.

Yet access to these drugs is tightly restricted. International clinical guidelines limit their use to patients with significant liver fibrosis—but not cirrhosis. Doctors use non-invasive tools like the FIB-4 score and elastography to identify who qualifies, reserving liver biopsy for uncertain cases. Large groups of patients are excluded entirely: those with established cirrhosis, anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, and patients with lean MASH, a form of the disease that occurs in people without obesity, where the drugs' safety and effectiveness remain unproven.

The regulatory warnings are substantial. These medications carry risks of severe gastrointestinal toxicity, acute kidney injury, gallstones, and pancreatitis. Nausea, vomiting, and diarrhea are common enough that a notable proportion of patients stop taking the drug. Rapid weight loss can trigger gallstone formation requiring surgery. Patients with severe gastroparesis or a history of pancreatitis must avoid these drugs entirely. Close monitoring is mandatory, and treatment must be tailored to each person's circumstances.

Approvals in the United States and Europe came with conditions: companies must continue their pivotal trials and prove that the liver improvements actually translate into reduced liver failure and lower mortality. International guidelines emphasize using these drugs only in patients at highest risk of disease progression, avoiding widespread or casual use. But even this cautious approach has created tension. In countries like the United Kingdom, health systems are grappling not just with whether the drugs work, but whether they can afford them and how to distribute them fairly. The World Health Organization has issued conditional recommendations for long-term use of these drugs in obesity, warning that costs are high and global availability is limited.

Demand has outpaced supply, leading to concerns about counterfeit and compounded versions flooding the market. Regulators are now proposing stricter controls to protect patients from fake medications. The fundamental challenge remains: these drugs are not a universal solution. Their benefits are confined to earlier stages of liver disease, to patients who meet specific phenotypic and risk criteria, and to those without disqualifying conditions. They require lifelong use. They are expensive. And they are not available everywhere. Any serious strategy to address metabolic liver disease and obesity must look beyond medication alone—to the social and environmental factors that drive these conditions in the first place.